SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TRON (TRX) is a cryptocurrency launched in 2018. TRON has a current supply of 95,022,365,191.094644 with 95,022,375,662.737444 in circulation. The last known price of TRON is 0.30232528 USD and is down -8.04 over the last 24 hours. It is currently trading on 1389 active market(s) with $1,465,217,312.79 traded over the last 24 hours. More information can be found at https://trondao.org/.

Tron

TRON is drawing attention as traders discuss a pullback after its prior rally, with technical posts debating whether support will hold or weakness will continue. Some holders view TRX as comparatively resilient and point to its use in stablecoin transfers, while others criticize its price performance and prolonged consolidation.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Attention centers on Candels CAN-2409 prostate-cancer program, with traders watching upcoming clinical data presentations and the planned BLA submission; bullish posters point to the positive Phase 3 results, while skeptics question the regulatory timeline, financing and CEO credibility. The debate is amplified by a sharp share-price decline that some attribute to broader biotech weakness and thin trading, while others see it as company-specific selling pressure.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons strong third-quarter earnings beat, led by growth in Dupixent and Eylea HD, has driven a sharp share-price breakout and renewed bullish momentum. Traders are celebrating the new high while watching legacy Eyleas decline and upcoming regulatory decisions as potential counterweights.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

Discussion centers on broad-market volatility and the Dows relative strength versus the tech-heavy Nasdaq, with traders debating whether the rotation can hold or whether weakening momentum will bring a wider selloff. Rising Treasury yields, Fed rate concerns, and Iran-related oil risks recur as bearish macro worries, while others see support for a continued rally.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

MAGS is drawing attention as traders debate weakness and rotation in the Magnificent Seven, with some seeing a pullback or support test and others expecting the mega-cap leaders to regain strength. The main bearish concern is whether heavy AI spending can deliver adequate returns, while bullish traders point to the groups resilience and potential to lead a rebound.

Barrick Mining Corp. engages in the production and sale of gold, copper, and related activities. It also provides exploration and mining development. It operates through the following business segments: Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, Bulyanhulu, and Other Mines. The company was founded by Peter D. Munk in 1983 and is headquartered in Toronto, Canada.

Barrick Mining Corp.

Barrick Mining Corp

Barrick is drawing attention as shares slide amid bearish technical calls for a deeper correction and reports of options activity skewed toward puts. Some traders see the weakness as a buying opportunity and remain bullish on gold miners longer term, while others expect further downside as precious metals weaken.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

Aetnas weaker 2027 Medicare Advantage star ratings are the main concern, with traders focused on potential pressure to future bonus revenue and margins. The discussion is bearish but divided over whether the setback is already priced in, especially as Humana rallied on stronger ratings.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

ARMs steep selloff and weakening technicals dominate discussion, with traders linking the drop to broader semiconductor weakness and concerns about Intels outlook and AI/CPU demand. Some see the pullback toward support as a buying opportunity, while others warn that high valuation and negative momentum could leave room for further declines ahead of earnings.

Magnite, Inc. provides a technology solution to automate the purchase and sale of digital advertising inventory for buyers and sellers. It features applications and services for digital advertising sellers including websites, mobile applications, and other digital media properties. The company was founded by Frank Addante, Duc Chau, Craig Roah, Julie Mattern and Brian D. Baumgart on April 20, 2007 and is headquartered in New York, NY.

Magnite Inc

Magnites strong quarterly results and raised full-year outlook, particularly continued growth in connected-TV advertising, are driving attention. Traders are broadly positive about the execution, while debating how quickly potential benefits from Google ad-tech remedies could add to growth.

ProShares Trust II - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

SCO is drawing attention as traders use the leveraged inverse crude-oil ETF to position for oil to fall amid volatile Iran and Strait of Hormuz headlines, with speculation about a deal or restored supply competing with fears of further escalation. Many are accumulating shares on expected declines in crude, while others complain that backwardation and daily-reset decay have weakened SCOs performance relative to oil moves.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Marcus (MCS) Q3 Earnings Lag Estimates

Marcus (MCS) delivered earnings and revenue surprises of -3.23% and +0.61%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Marcus (MCS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Marcus (MCS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Marcus Corporation Reports Third Quarter 2026 Results

The Marcus Corporation (NYSE: MCS) today reported results for the third quarter 2026 ended September 30, 2026. Record third quarter revenue in both divisions drove the highest total revenue for any quarter in company history, said Gregory S. Marcus, chief executive officer of Marcus Corporation. In...

CNK vs. MCS: Which Theater Stock Is the Better Buy Today?

Cinemark outshines Marcus with stronger earnings revisions, premium-format expansion and stock gains, making it the preferred pick amid the theatrical recovery.

This Movie Theater Chain Stock Has Outperformed Peers With 86% Gains In 2026: Wall Street Sees Further Upside

Equity

AMC Entertainment Holdings has surged past its peers in 2026 amid box office records and strong financial performance. 

Marcus (MCS) Earnings Expected to Grow: Should You Buy?

Marcus (MCS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Marcus Corporation Announces Third Quarter 2026 Release Date and Conference Call

Marcus Corporation (NYSE: MCS) today announced it will report results for the third quarter of 2026 prior to the stock market open on Thursday, October 29, 2026. The release will be followed by a conference call at 10:00 a.m. Central/11:00 a.m. Eastern time. Participants may listen to the call live...

Cinemark Stock Gains 12% in a Month: Should You Buy, Hold or Sell?

CNK's shares rally as record summer box office, premium-format expansion and rising earnings estimates strengthen its appeal as a buying opportunity.

AMC Stock Gains 20% in a Month: Should Investors Ride the Rally?

AMC's 20% monthly rally is backed by stronger theater demand, premium-screen growth and lower interest costs, while valuation remains discounted.

Cinemark's Digital Marketing Push: Can It Strengthen Customer Loyalty?

CNK is leveraging 40 million addressable customers, personalized promotions and influencer campaigns to attract younger moviegoers and boost repeat visits.

• Reported GAAP EPS of $0.60 up 15.38% YoY
• Reported revenue of $237.75M up 13.13% YoY

Marcus Corporation's hotel operating results declined amid storm-related repairs and lost revenue; theatre admission growth faced a comparison effect, while film availability, audience appeal, and release-window dynamics remain identified risks.

Marcus Corporation posted record theatre revenue and operating income, higher attendance and per-person spending, while owned-hotel RevPAR grew and comparable properties outperformed competitive sets during Q3.

Marcus Corp. engages in the lodging and entertainment industries. It operates through the following business segments: Theatres and Hotels & Resorts. The Theatres segment includes multiscreen motion picture theatres and a family entertainment center. The Hotels & Resorts segment owns and operates full service hotels and resorts. The company was founded by Ben Marcus on November 1, 1935 and is headquartered in Milwaukee, WI.

Marcus Corp.

Bullish Sentiment

<ul class="summary-bullets"><li>AMC stock has gained about 86% so far this year, outperforming IMAX, Cinemark Holdings and Marcus Corp.</li><li>Roth Capital raised its price target on AMC Entertainment to $3.25 from $3 and maintained a ‘Neutral’ rating on the shares, implying about 12% upside from its last close.&nbsp;</li><li>The analyst said that it is raising its third-quarter estimates on AMC to reflect record domestic box office and stronger-than-expected European growth.&nbsp;</li></ul><p>AMC Entertainment Holdings (AMC) shares have rallied in 2026, soaring past its peers as booming box office collections, record financial results, and major debt restructuring have worked in its favor.&nbsp;</p><p><a href="https://stocktwits.com/symbol/AMC">AMC stock</a> has gained about 86% so far this year,&nbsp;outperforming&nbsp;<a href="https://stocktwits.com/symbol/IMAX">Imax Corp. (IMAX)</a>,&nbsp;<a href="https://stocktwits.com/symbol/CNK">Cinemark Holdings Inc. (CNK)</a>, and&nbsp;<a href="https://stocktwits.com/symbol/MCS">Marcus Corp. (MCS)</a>.&nbsp;</p><figure class="image"><img src="https://news.stocktwits-cdn.com/koyfin_20261026_053227652_9c8dad7d19.png" alt="koyfin_20261026_053227652.png" width="2400" height="1500"></figure><p>Meanwhile, Roth Capital raised its price target on AMC Entertainment to $3.25 from $3 and maintained a ‘Neutral’ rating on the shares, implying about 12% upside from its last close.&nbsp;</p><h2 class="st-heading-2">Analyst Rationale On AMC Stock</h2><p>The analyst said that it is raising its third-quarter (Q3) estimates on AMC to reflect record domestic box office and stronger-than-expected European growth, with notable market share gains given its sizable IMAX exposure and the stellar performance of The Odyssey.&nbsp;</p><p>AMC recorded 4.3 million visitors during the film's opening weekend, marking its largest R-rated opening since 2024. The Odyssey crossed $286 million in North America and $640 million worldwide shortly after launch, later scaling past $1.1 billion globally to become one of the highest-grossing IMAX releases in history.</p><p>Meanwhile, in the second quarter, AMC Entertainment’s European operations delivered about an 18% year-over-year increase in attendance that outperformed the broader European industry growth rate of 16.2%. International revenues climbed 19.2% year-over-year to $338.1 million, boosted by about 2% from European currency appreciation.&nbsp;</p><h2 class="st-heading-2">AMC Stock: Q3 Expectations&nbsp;</h2><p>The movie theater chain is expected to report third-quarter (Q3) results after market hours on Nov. 4.&nbsp;</p><p>According to Fiscal.ai estimates, analysts expect the company to post $1.62 billion in revenue for the quarter, up 24%. Meanwhile, earnings per share are forecast at $0.1, compared to a loss of $0.58 per share the previous year.&nbsp;</p><h2 class="st-heading-2">AMC Stock: Retail Stance</h2><p>On Stocktwits, retail sentiment around AMC stock was ‘bearish’ at the time of writing amid ‘low’ message volumes.&nbsp;</p><p>AMC stock was trading in the green in the overnight session late Sunday.&nbsp;</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

 In this photo illustration, a smartphone displays the logo of AMC Entertainment Holdings, Inc.

AMC Entertainment Holdings

Cinemark Holdings Inc

Imax Corp

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	$0.23	--	--	N/A
Q3 '26	$0.60	$0.60	0.13%	BEAT
Q2 '26	$0.35	$0.51	44.68%	BEAT
Q1 '26	-$0.52	-$0.51	1.92%	BEAT
Q4 '25	$0.06	$0.19	202.55%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

MCS Earnings

Latest Earnings Results: Q3 '26

Historical Earnings